文献速递其他结缔组织病血管炎

系统性硬化症相关肺动脉高压中心包积液的预后意义:PHAROS登记研究分析

Prognostic significance of pericardial effusion in systemic sclerosis-associated pulmonary hypertension: analysis from the PHAROS Registry.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

基于PHAROS前瞻性多中心登记研究,纳入2005至2016年新诊断的系统性硬化症相关肺动脉高压患者。335例经右心导管确诊且超声心动图记录心包积液状态的患者中,166例(50%)曾出现心包积液,曾出现心包积液对生存无预测价值(log-rank检验P=0.49)。在245例至少接受两次超声心动图检查的患者中,44%在平均4.3年随访期间心包积液状态发生变化;持续性心包积液是生存的独立预测因素(校正风险比=2.34,95%CI 1.20至4.64,P=0.002),而间歇性心包积液不是生存预测因素(校正风险比=0.89,95%CI 0.52至1.56,P=0.68)。

要点

  • 在系统性硬化症相关肺动脉高压患者中,50%(166/335)曾出现心包积液,但曾出现心包积液对生存无预测价值(log-rank检验P=0.49)。
  • 245例至少接受两次超声心动图检查的患者中,44%在平均4.3年随访期间心包积液状态发生变化。
  • 持续性心包积液是生存的独立预测因素(校正风险比=2.34,95%CI 1.20至4.64,P=0.002),间歇性心包积液不是生存预测因素(校正风险比=0.89,95%CI 0.52至1.56,P=0.68)。

核心结论

  • 持续性心包积液,而非曾出现心包积液或间歇性心包积液,与更差的生存独立相关。

研究设计与样本

  • PHAROS为前瞻性多中心登记研究,纳入2005至2016年新诊断的系统性硬化症相关肺动脉高压患者。
  • 分析335例经右心导管确诊且超声心动图记录心包积液有无的患者,以及245例至少接受两次超声心动图检查的患者。

主要发现

  • 335例患者中166例(50%)曾出现心包积液,曾出现心包积液对生存无预测价值(log-rank检验P=0.49)。
  • 245例至少接受两次超声心动图检查的患者中,44%在平均4.3年随访期间心包积液状态发生变化。
  • 持续性心包积液是生存的独立预测因素(校正风险比=2.34,95%CI 1.20至4.64,P=0.002)。
  • 间歇性心包积液不是生存预测因素(校正风险比=0.89,95%CI 0.52至1.56,P=0.68)。

临床怎么用

  • 作者认为,整合系列超声心动图信息可能帮助临床医生更好地判断系统性硬化症相关肺动脉高压患者的生存预后。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Pulmonary hypertension (PH) is a leading cause of death in patients with SSc. The purpose of this study was to determine the prognostic significance of pericardial effusion in patients with SSc-PH. METHODS: Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) is a prospective multicentre registry which enrolled patients with newly diagnosed SSc-PH from 2005 to 2016. The prognostic impact of pericardial effusion status, including those who ever or never had pericardial effusion, and those who had persistent or intermittent pericardial effusion, was analysed. Kaplan-Meier survival analyses, log-rank test, and multivariable Cox proportional hazards regression were performed. RESULTS: Of the 335 patients with SSc-PH diagnosed by right heart catheterization and documentation of pericardial effusion presence or absence on echocardiogram, 166 (50%) ever had pericardial effusion. Ever having pericardial effusion was not predictive of survival (log-rank test P = 0.49). Of the 245 SSc-PH patients who had at least two echocardiograms, 44% had a change in pericardial effusion status over an average of 4.3 years of follow up. Having a persistent pericardial effusion was an independent predictor of survival [adjusted hazard ratio (aHR)=2.34, 95% CI 1.20, 4.64, P = 0.002], while intermittent pericardial effusion was not a predictor of survival (aHR = 0.89, 95% CI 0.52, 1.56, P = 0.68), in a multivariable-adjusted analysis. CONCLUSION: Persistent pericardial effusion, but not ever having had pericardial effusion or intermittent pericardial effusion, was independently associated with poorer survival. Incorporating information from serial echocardiograms may help clinicians better prognosticate survival in their SSc-PH patients.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Luo Y, Gordon JK, Xu J, et al. Prognostic significance of pericardial effusion in systemic sclerosis-associated pulmonary hypertension: analysis from the PHAROS Registry. Rheumatology (Oxford). 2024. PMID: 37478347. doi:10.1093/rheumatology/kead368

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。